Background In a previous phase 3 clinical trial, we showed that an inactivated poliovirus
vaccine derived from the Sabin strain (sIPV) can induce neutralising antibodies against …

Background Sabin strain inactivated poliovirus vaccine (hereinafter as “sIPV”) has been
marketed globally in recent years, and more data on its immune persistence are needed …

Background The immunogenicity and safety of the sequential schedule of Sabin strain-
based inactivated poliovirus vaccine (sIPV) and bivalent oral poliovirus vaccine (bOPV) …

Background The development of a Sabin strain–based inactivated poliovirus vaccine (Sabin-
IPV) is imperative to protecting against vaccine-associated paralytic poliomyelitis in …

Abstract Background. The production of Sabin inactivated poliovirus vaccine (IPV) can
reduce biosafety requirements in the posteradication/post–oral poliovirus vaccine (OPV) era …

Introduction We conducted a follow-on study to a phase I randomized, controlled trial
conducted in Cuba, 2012, to assess the persistence of poliovirus antibodies at 21–22 …

Background. A Sabin strain–based inactivated poliomyelitis vaccine (Sabin-IPV) is the
rational option for completely eradicating poliovirus transmission. The neutralizing capacity …

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new
inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on …

Background A new inactivated polio vaccine made from Sabin strains (sIPV) was developed
as part of the global polio eradication initiative. Methods This randomized, double-blind …

Background In order to completely eradicate polio caused by wild poliovirus infection as well
as vaccine-associated paralytic polio (VAPP), Sabin inactivated poliovirus vaccine (sIPV) …